Allergan, a global pharmaceutical leader, is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. It markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories. Allergan is an industry consolidator in the specialty pharma and branded generics sector. It has grown rapidly by multiple acquisitions, including Watson Pharma, Warner Chilcott and Forest Laboratories. It sold its generic drug business to Teva in 2015. Allergan in Ireland Company in Ireland Allergan plc is registered in Ireland and employs over 2,000 people in Ireland. The company has IDA-supported development and manufacturing operations in Westport, Co. Mayo, Galway and Clonshaugh Dublin. It has global supply chain management functions in central Dublin. Allergan has invested over €670 million in its Irish operations and continues to invest in Ireland. As well as a €42 million investment program in Ireland in 2017, and €50 million invested in 2018, in April 2019, Allergan announced a €65 million capital investment programme to facilitate the continued expansion of the company’s state-of-the-art laboratories and manufacturing campuses at Westport in County Mayo and Clonshaugh in north Dublin. The Westport facility has created 63 new highly skilled jobs. “This €65 million investment further cements Ireland’s strategic role in Allergan’s global network. Continued investment of this scale builds on the €50 million investment programme in 2018 and €42 million in 2017 which allows us to apply world-class technology to Allergan’s leading innovation and product development strategy. We are expanding capacity to meet global demand and we are advancing our R&D capabilities to meet the needs of the future for our business. We are proud that 40 years on we are still growing and offering valuable employment opportunities in key regions of Ireland and we thank the communities around us for their continued support.” Mr. Paul Coffey, Vice President & Plant General Manager, Allergan Westport, In 2017 the company announced a $50,000 life sciences innovation award program in co-operation with six 3rd level colleges in Ireland. It also announced a three-year deal as the Official Sponsor of the Dubai Duty Free Irish Open. In 2017 Allergan acquired the Galway-based operation of Zeltiq Aesthetics, a medical technology company focused on developing and commercializing products utilizing proprietary controlled-cooling technology for body contouring. In 2016 Zeltiq had established its European manufacturing facility in Galway. The operation currently employs around 130 people. Westport, Co. Mayo Westport, Allergan’s largest operation, employs 1,240 people. It is the world’s principal site for the manufacture of Botox and Restasis. The majority of product lines manufactured at the Westport campus are related to eye care (such as Restasis, Alphagan and Refresh). Botox, the other major output from the facility is used for medicinal and cosmetic purposes. Clonshaugh, Dublin The Clonshaugh facility produces solid dose pharmaceuticals, many of which address conditions such as depression (e.g. Lexapro and Celexa), Alzheimer’s disease (Namenda, Namzaric), hypertension (Bystolic), Fibromyalgia (Savella), IBS (Linzess) and Biopolar Disorder (Vraylar). Rahoon, Galway The Rahoon facility develops and commercials products utilizing proprietary controlled-cooling technology for body contouring. Earlsfort Terrace, Dublin The Allergan’s international supply chain office established in 1996, provides a range of customer services and commercial support activities.